Thus, oncolytic adenovirus-mediated p53 overexpression appears to be a promising anti-tumor strategy for improving the efficacy of ICIs against PDAC tumors by strongly enhancing ICD and the anti-tumor immune response. Here, TP53 is linked to neoplasm.